GlobeNewswire Inc.··Aclarion, Inc.Aclarion Charts Path to Growth With 2026 Reimbursement Push and Clinical Readouts
Aclarion outlines 2026 priorities: pursuing regional insurance reimbursement, releasing CLARITY trial results in Q4 2026, and expanding Nociscan adoption. Strong balance sheet extends to 2028.
ACONACONWbalance sheetchronic low back pain